These results indicate that SCA alone has achieved PFS and OS benefits that are not inferior to single-agent DOX in the second-line treatment of advanced/metastatic NSCLC with wild-type or unknown EGFR status. This evidence concerns the gene EGFR and non-small cell lung carcinoma.